Vir Biotechnology Inc (VIR)

Current ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total current assets	US$ in thousands	1,042,460	1,047,160	1,205,740	1,213,100	1,588,230	1,769,180	1,946,330	2,358,630	2,519,080	2,413,620	2,288,270	2,567,550	1,562,820	1,066,340	862,295	993,114	772,365	849,572	578,761	377,541
Total current liabilities	US$ in thousands	119,662	117,161	96,412	94,068	175,407	165,050	225,623	485,288	511,029	308,203	477,868	702,361	341,242	233,724	146,024	361,099	99,064	76,998	54,940	56,396
Current ratio		8.71	8.94	12.51	12.90	9.05	10.72	8.63	4.86	4.93	7.83	4.79	3.66	4.58	4.56	5.91	2.75	7.80	11.03	10.53	6.69

December 31, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $1,042,460K ÷ $119,662K
= 8.71

The current ratio of Vir Biotechnology Inc has fluctuated over the past few years, indicating changes in the company's liquidity position. The current ratio is a measure of the company's ability to meet its short-term obligations with its current assets.

From March 31, 2020, to June 30, 2020, the current ratio increased significantly from 6.69 to 10.53, reflecting a strong liquidity position. It continued to improve to 11.03 by September 30, 2020. However, by December 31, 2020, there was a slight decline to 7.80.

Subsequently, the current ratio experienced more significant fluctuations, dropping to 2.75 by March 31, 2021, indicating potential liquidity challenges. The ratio recovered to 5.91 by June 30, 2021, but then decreased to 4.56 by September 30, 2021.

Throughout the following quarters, the current ratio continued to fluctuate within a range, showing some stability but still below the levels seen in early 2020. By December 31, 2024, the current ratio stood at 8.71, indicating an improvement in liquidity compared to the earlier periods, although it did not reach the peak levels seen in mid-2020.

Overall, the current ratio analysis suggests that Vir Biotechnology Inc has experienced variations in its liquidity position over the period, with some fluctuations reflecting changes in the company's ability to cover its short-term liabilities with its current assets. Further monitoring and analysis are necessary to assess the company's ongoing liquidity health and financial stability.